exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356375 RNA Name: hsa-miR-1321 RNA Type: miRNA Chromosome: chrX Starnd: + Coordinate: Start Site(bp): 85835832 End Site(bp): 85835849 External Links: hsa-miR-1321

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand DDAH1 chr1 85318481 85578363 - WASF2 chr1 27404230 27490167 - KDM5C chrX 53191321 53225422 - C19orf47 chr19 40319536 40348527 - UBE2Q1 chr1 154548577 154559028 - KLC2 chr11 66257294 66267860 + CBFA2T3 chr16 88874858 88977207 - ENSA chr1 150600851 150629612 - ZDHHC9 chrX 129803288 129843909 - MKNK2 chr19 2037465 2051244 - AKIRIN1 chr1 38991276 39006059 + NRF1 chr7 129611720 129757082 + REEP4 chr8 22138020 22141951 - BCL7A chr12 122019422 122062044 + CBX5 chr12 54230942 54280133 - SOX13 chr1 204073115 204127743 + LENG8 chr19 54448887 54462037 + CCND3 chr6 41934933 42050357 - STK35 chr20 2101827 2177038 + GPI chr19 34359480 34402413 + RCOR1 chr14 102592649 102730561 + ONECUT2 chr18 57435374 57491298 + SPTBN2 chr11 66685248 66729226 - WSB2 chr12 118032694 118062430 - ARID1A chr1 26693236 26782104 + HMGA1 chr6 34236873 34246231 + RARA chr17 40309180 40357643 + TP53 chr17 7661779 7687550 - TPP1 chr11 6612768 6619448 - SCD chr10 100347233 100364826 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC022167.2 chr16 8848105 8860456 + AC069281.2 chr7 100572232 100578700 - AC124068.2 chr15 89335053 89336161 + AP000233.2 chr21 25095022 25103670 + HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - MALAT1 chr11 65497688 65506516 + MIR22HG chr17 1711493 1717174 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + TYMSOS chr18 630886 658340 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.